Grant List
Represents Grant table in the DB
GET /v1/grants?page%5Bnumber%5D=1392&sort=award_id
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=award_id", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1419&sort=award_id", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1393&sort=award_id", "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1391&sort=award_id" }, "data": [ { "type": "Grant", "id": "15540", "attributes": { "award_id": "75N91024P00397-0-0-1", "title": "NCI PATTERNS OF CARE STUDY-DIAGNOSIS YEAR 2021 (PROSTATE CANCER AND OVARIAN CANCER)", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Cancer Institute (NCI)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2024-05-01", "end_date": "2025-04-30", "award_amount": 244943, "principal_investigator": { "id": 32084, "first_name": "ANSHU", "last_name": "SHRESTHA", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1188, "ror": "https://ror.org/019621n74", "name": "Public Health Institute", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "The National Cancer Institute (NCI) Patterns of Care (POC) studies describe, characterize, and compare practice patterns and treatments provided for cancer in different geographic areas of the United States. POC Studies are conducted periodically, typically annually, to satisfy a congressional directive (under Public Law 100-607, Sec. 413 (a)(2)(C) adopted on November 4, 1988) to the NCI to “assess the incorporation of state-of-the-art cancer treatments into clinical practice and the extent to which cancer patients receive such treatments and include the results of such assessment in the biennial reports…”. To satisfy the directive and to update and enhance the utility of the POC Studies, a working group including representatives from the NCI’s Divisions of Cancer Control and Population Sciences and Cancer Treatment and Diagnosis and a representative from the American Cancer Society was developed to review knowledge gaps in cancer therapy dissemination and to develop priority areas for study. The group reached a consensus that a gap remains regarding factors associated with guideline use of biomarker tests and targeted therapy. Furthermore, the group determined there is limited information about the effects of the COVID-19 pandemic on cancer screening, diagnosis, treatment, and receipt of supportive/palliative care among individuals diagnosed with cancer. For feasibility reasons, the group also recommended that this POC Study be focused specifically on the patterns of care for patients newly diagnosed with prostate or ovarian cancer. This POC Study will also collect data on documentation of palliative care and patient financial impacts of the COVID-19 pandemic. Relevant information on cancer diagnosis, cancer recurrence and metastasis, patterns of care (e.g., utilization of biomarker testing, specific cancer treatments, supportive/palliative care), and patient financial stability shall be abstracted from medical records among patients aged 20 years of older who were diagnosed with prostate or ovarian cancer in 2021.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "15504", "attributes": { "award_id": "75N91024P00404-0-0-1", "title": "NCI PATTERNS OF CARE STUDY- DIAGNOSIS YEAR 2021 (PROSTATE CANCER AND OVARIAN CANCER)", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Cancer Institute (NCI)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2024-05-01", "end_date": "2025-04-30", "award_amount": 86402, "principal_investigator": { "id": 32050, "first_name": "Marylou", "last_name": "Gonsalves", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 2547, "ror": "", "name": "CONNECTICUT STATE DEPT OF PUBLIC HEALTH", "address": "", "city": "", "state": "CT", "zip": "", "country": "United States", "approved": true }, "abstract": "The National Cancer Institute (NCI) Patterns of Care (POC) studies describe, characterize, and compare practice patterns and treatments provided for cancer in different geographic areas of the United States. POC Studies are conducted periodically, typically annually, to satisfy a congressional directive (under Public Law 100-607, Sec. 413 (a)(2)(C) adopted on November 4, 1988) to the NCI to “assess the incorporation of state-of-the-art cancer treatments into clinical practice and the extent to which cancer patients receive such treatments and include the results of such assessment in the biennial reports…”. To satisfy the directive and to update and enhance the utility of the POC Studies, a working group including representatives from the NCI’s Divisions of Cancer Control and Population Sciences and Cancer Treatment and Diagnosis and a representative from the American Cancer Society was developed to review knowledge gaps in cancer therapy dissemination and to develop priority areas for study. The group reached a consensus that a gap remains regarding factors associated with guideline use of biomarker tests and targeted therapy. Furthermore, the group determined there is limited information about the effects of the COVID-19 pandemic on cancer screening, diagnosis, treatment, and receipt of supportive/palliative care among individuals diagnosed with cancer. For feasibility reasons, the group also recommended that this POC Study be focused specifically on the patterns of care for patients newly diagnosed with prostate or ovarian cancer. This POC Study will also collect data on documentation of palliative care and patient financial impacts of the COVID-19 pandemic. Relevant information on cancer diagnosis, cancer recurrence and metastasis, patterns of care (e.g., utilization of biomarker testing, specific cancer treatments, supportive/palliative care), and patient financial stability shall be abstracted from medical records among patients aged 20 years or older who were diagnosed with prostate or ovarian cancer in 2021.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "15507", "attributes": { "award_id": "75N91024P00410-0-0-1", "title": "NCI PATTERNS OF CARE STUDY - DIAGNOSIS YEAR 2021 (PROSTATE CANCER AND OVARIAN CANCER)", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Cancer Institute (NCI)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2024-05-01", "end_date": "2025-04-30", "award_amount": 104718, "principal_investigator": { "id": 32052, "first_name": "STEPHEN M", "last_name": "SCHWARTZ", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 2062, "ror": "", "name": "FRED HUTCHINSON CANCER CENTER", "address": "", "city": "", "state": "WA", "zip": "", "country": "United States", "approved": true }, "abstract": "The National Cancer Institute (NCI) Patterns of Care (POC) studies describe, characterize, and compare practice patterns and treatments provided for cancer in different geographic areas of the United States. POC Studies are conducted periodically, typically annually, to satisfy a congressional directive (under Public Law 100-607, Sec. 413 (a)(2)(C) adopted on November 4, 1988) to the NCI to “assess the incorporation of state-of-the-art cancer treatments into clinical practice and the extent to which cancer patients receive such treatments and include the results of such assessment in the biennial reports…”. To satisfy the directive and to update and enhance the utility of the POC Studies, a working group including representatives from the NCI’s Divisions of Cancer Control and Population Sciences and Cancer Treatment and Diagnosis and a representative from the American Cancer Society was developed to review knowledge gaps in cancer therapy dissemination and to develop priority areas for study. The group reached a consensus that a gap remains regarding factors associated with guideline use of biomarker tests and targeted therapy. Furthermore, the group determined there is limited information about the effects of the COVID-19 pandemic on cancer screening, diagnosis, treatment, and receipt of supportive/palliative care among individuals diagnosed with cancer. For feasibility reasons, the group also recommended that this POC Study be focused specifically on the patterns of care for patients newly diagnosed with prostate or ovarian cancer. This POC Study will also collect data on documentation of palliative care and patient financial impacts of the COVID-19 pandemic. Relevant information on cancer diagnosis, cancer recurrence and metastasis, patterns of care (e.g., utilization of biomarker testing, specific cancer treatments, supportive/palliative care), and patient financial stability shall be abstracted from medical records among patients aged 20 years or older who were diagnosed with prostate or ovarian cancer in 2021.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "15503", "attributes": { "award_id": "75N91024P00411-0-0-1", "title": "NCI PATTERNS OF CARE STUDY FY24 - DIAGNOSIS YEAR 2021 (PROSTATE CANCER AND OVARIAN CANCER)", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Cancer Institute (NCI)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2024-05-01", "end_date": "2025-04-30", "award_amount": 193220, "principal_investigator": { "id": 32049, "first_name": "ERIC", "last_name": "DURBIN", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1162, "ror": "https://ror.org/02k3smh20", "name": "University of Kentucky", "address": "", "city": "", "state": "KY", "zip": "", "country": "United States", "approved": true }, "abstract": "The National Cancer Institute (NCI) Patterns of Care (POC) studies describe, characterize, and compare practice patterns and treatments provided for cancer in different geographic areas of the United States. POC Studies are conducted periodically, typically annually, to satisfy a congressional directive (under Public Law 100-607, Sec. 413 (a)(2)(C) adopted on November 4, 1988) to the NCI to “assess the incorporation of state-of-the-art cancer treatments into clinical practice and the extent to which cancer patients receive such treatments and include the results of such assessment in the biennial reports…”. To satisfy the directive and to update and enhance the utility of the POC Studies, a working group including representatives from the NCI’s Divisions of Cancer Control and Population Sciences and Cancer Treatment and Diagnosis and a representative from the American Cancer Society was developed to review knowledge gaps in cancer therapy dissemination and to develop priority areas for study. The group reached a consensus that a gap remains regarding factors associated with guideline use of biomarker tests and targeted therapy. Furthermore, the group determined there is limited information about the effects of the COVID-19 pandemic on cancer screening, diagnosis, treatment, and receipt of supportive/palliative care among individuals diagnosed with cancer. For feasibility reasons, the group also recommended that this POC Study be focused specifically on the patterns of care for patients newly diagnosed with prostate or ovarian cancer. This POC Study will also collect data on documentation of palliative care and patient financial impacts of the COVID-19 pandemic. Relevant information on cancer diagnosis, cancer recurrence and metastasis, patterns of care (e.g., utilization of biomarker testing, specific cancer treatments, supportive/palliative care), and patient financial stability shall be abstracted from medical records among patients aged 20 years or older who were diagnosed with prostate or ovarian cancer in 2021.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "15505", "attributes": { "award_id": "75N91024P00413-0-0-1", "title": "NCI PATTERNS OF CARE STUDY FY24 - DIAGNOSIS YEAR 2021 (PROSTATE CANCER AND OVARIAN CANCER)", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Cancer Institute (NCI)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2024-05-01", "end_date": "2025-04-30", "award_amount": 99442, "principal_investigator": { "id": 32051, "first_name": "LAUREN", "last_name": "MANISCALCO", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1202, "ror": "", "name": "LSU HEALTH SCIENCES CENTER", "address": "", "city": "", "state": "LA", "zip": "", "country": "United States", "approved": true }, "abstract": "The National Cancer Institute (NCI) Patterns of Care (POC) studies describe, characterize, and compare practice patterns and treatments provided for cancer in different geographic areas of the United States. POC Studies are conducted periodically, typically annually, to satisfy a congressional directive (under Public Law 100-607, Sec. 413 (a)(2)(C) adopted on November 4, 1988) to the NCI to “assess the incorporation of state-of-the-art cancer treatments into clinical practice and the extent to which cancer patients receive such treatments and include the results of such assessment in the biennial reports…”. To satisfy the directive and to update and enhance the utility of the POC Studies, a working group including representatives from the NCI’s Divisions of Cancer Control and Population Sciences and Cancer Treatment and Diagnosis and a representative from the American Cancer Society was developed to review knowledge gaps in cancer therapy dissemination and to develop priority areas for study. The group reached a consensus that a gap remains regarding factors associated with guideline use of biomarker tests and targeted therapy. Furthermore, the group determined there is limited information about the effects of the COVID-19 pandemic on cancer screening, diagnosis, treatment, and receipt of supportive/palliative care among individuals diagnosed with cancer. For feasibility reasons, the group also recommended that this POC Study be focused specifically on the patterns of care for patients newly diagnosed with prostate or ovarian cancer. This POC Study will also collect data on documentation of palliative care and patient financial impacts of the COVID-19 pandemic. Relevant information on cancer diagnosis, cancer recurrence and metastasis, patterns of care (e.g., utilization of biomarker testing, specific cancer treatments, supportive/palliative care), and patient financial stability shall be abstracted from medical records among patients aged 20 years or older who were diagnosed with prostate or ovarian cancer in 2021.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "7749", "attributes": { "award_id": "75N92019D00033-P00002-759201900074-1", "title": "REDS-IV-P - CENTER FOR TRANSFUSION LABORATORY STUDIES (CTLS) - SARS-CoV-2/COVID-19 STUDIES", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2019-04-01", "end_date": "2021-03-31", "award_amount": 4748941, "principal_investigator": { "id": 23549, "first_name": "MICHAEL Paul", "last_name": "BUSCH", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1617, "ror": "", "name": "VITALANT", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1617, "ror": "", "name": "VITALANT", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "This project will focus on key blood safety issues with COVID-19 and further our understanding of SARS-CoV-2 natural history and pathogenesis.", "keywords": [ "2019-nCoV", "Blood", "Blood Transfusion", "COVID-19", "Laboratory Study", "Natural History", "Pathogenesis", "Prevention", "Safety", "Transfusion", "transmission process" ], "approved": true } }, { "type": "Grant", "id": "9455", "attributes": { "award_id": "75N92019P00328-P00007-0-1", "title": "THE PURPOSE OF THIS MODIFICATION IS TO EXTEND LINE ITEM 1005 TO 1/31/21 FOR CONTINUING ENTREPRENEURIAL SERVICES FOR THE COVID-19 PANDEMIC.", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Biomedical Imaging and Bioengineering (NIBIB)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2019-08-16", "end_date": "2021-08-15", "award_amount": 3000026, "principal_investigator": { "id": 23963, "first_name": "ELIAS", "last_name": "CARO", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": null, "abstract": "The National Institute of Biomedical Imaging and Bioengineering (NIBIB) has an open solicitation for proposals to provide up to $500 million across multiple projects to rapidly produce innovative SARS-CoV-2 diagnostic tests that will assist the public’s safe return to normal activities. Rapid Acceleration of Diagnostics (RADx), is a fast-track technology development program that leverages the National Institutes of Health (NIH) Point-of-Care Technology Research Network (POCTRN). RADx will support novel solutions that build the U.S. capacity for SARS-CoV-2 testing up to 100-fold above what is achievable with standard approaches. RADx is structured to deliver innovative testing strategies to the public as soon as late summer 2020 and is an accelerated and comprehensive multi-pronged effort by NIH to make SARS-CoV-2 testing readily available to every American.", "keywords": [ "American", "COVID-19", "COVID-19 detection", "COVID-19 diagnostic", "COVID-19 pandemic", "COVID-19 testing", "Centers for Disease Control and Prevention (U.S.)", "Clinical", "Contracts", "Department of Defense", "Development", "Device Designs", "Diagnostic tests", "Ensure", "Exhalation", "Funding", "Goals", "Home", "Improve Access", "Laboratories", "Life Cycle Stages", "Modification", "National Institute of Biomedical Imaging and Bioengineering", "Patients", "Performance", "Point of Care Technology", "Privatization", "Program Development", "RADx", "Readiness", "Research", "Saliva", "Sampling", "Seasons", "Sensitivity and Specificity", "Services", "Speed", "Structure", "Technology", "Test Result", "Testing", "Time", "TimeLine", "United States National Institutes of Health", "Validation", "Virus", "base", "commercialization", "cost", "design", "detection limit", "flu", "handheld mobile device", "home test", "improved", "innovation", "meetings", "novel", "point of care", "product development", "programs", "scale up", "technology development", "user-friendly" ], "approved": true } }, { "type": "Grant", "id": "9130", "attributes": { "award_id": "75N92020C00006-P00004-9999-1", "title": "RAPID ACCELERATION OF DIAGNOTICS (RADX) ADVANCED TECHNOLOGIES PLATFORM RAPID ACCELERATION OF DIAGNOTICS (RADX) ADVANCED TECHNOLOGIES PLATFORM PROJECT", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Biomedical Imaging and Bioengineering (NIBIB)", "NIH Office of the Director" ], "program_reference_codes": [], "program_officials": [], "start_date": "2020-07-30", "end_date": "2021-07-29", "award_amount": 5665290, "principal_investigator": { "id": 24909, "first_name": "JAMES", "last_name": "LU", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1799, "ror": "", "name": "HELIX", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1799, "ror": "", "name": "HELIX", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "To enable reopening and monitoring of industrial, educational, and public sectors, widespread diagnostic testing for SARS-CoV-2 is needed. Rapid scale up is required to meet the testing needs in the US. Helix OPCO, LLC will establish an FDA-approved polymerase chain reaction (PCR) SARS-CoV-2 test, under Emergency Use Authorization (EUA), and perform testing in a CLIA-certified laboratory. Testing capacity will be incrementally scaled up to establish a high-throughput laboratory capable of daily processing of 25k, then 50k, then 100k, and finally 150k PCR tests with processing and analysis completed within a day of sample receipt. A subset of samples will undergo full viral genome sequencing, with sequences uploaded to GISAID and other public databases. Characterized samples will be provided to the RADx Variants Task Force to ensure that testing technologies are capable of detecting the full spread of SARS-CoV-2 variants. Expanded testing capacity through an FDA EUA method will support the needs of the US to monitor viral spread, detect variants, and inform reopening and mitigation efforts", "keywords": [ "Acceleration", "Address", "Advisory Committees", "CLIA certified", "COVID-19 test", "COVID-19 testing", "Databases", "Diagnostic tests", "Ensure", "FDA Emergency Use Authorization", "FDA approved", "Industrialization", "Laboratories", "Logistics", "Methods", "Monitor", "Polymerase Chain Reaction", "Process", "Public Sector", "RADx", "RADx Advanced Technology Platforms", "Reagent", "Reproducibility", "SARS-CoV-2 variant", "Sampling", "Ships", "Specificity", "Specimen", "Technology", "Testing", "Training", "United States National Institutes of Health", "Variant", "Viral", "Viral Genome", "design", "genome sequencing", "laboratory equipment", "next generation sequencing", "risk mitigation", "sample collection", "scale up" ], "approved": true } }, { "type": "Grant", "id": "9141", "attributes": { "award_id": "75N92020C00009-P00002-9999-1", "title": "RADX PROGRAM: TECH PROJECT NO 6114 FLUIDIGM ADVANTA DX SARS-COV-2 RT-PCR ASSAY FOR SALIVA", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Biomedical Imaging and Bioengineering (NIBIB)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2020-07-30", "end_date": "2021-09-30", "award_amount": 8580056, "principal_investigator": { "id": 24916, "first_name": "ANDREW", "last_name": "QUONG", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1801, "ror": "", "name": "FLUIDIGM CORPORATION", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1801, "ror": "", "name": "FLUIDIGM CORPORATION", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "Fluidigm's BioMark HD microfluidics platform addresses the massive demand for SARS-CoV-2 PCR testing- combining speed, minimal cost, and massive throughput unparalleled in the industry. Further advantages include flexibility to rapidly integrate new mutational markers or increase panel size to include additional infectious agents. This platform works with all clinical sample types. 1) Technology Development Our solution leverages Advantaâ„¢ Dx SARS-CoV-2 RT-PCR Assay submitted for an EUA, and two assays under development that can change the landscape for detection. This assay allows for up to 6000 samples per day on a single system. Additional assays address different needs in testing, throughput, specificity and sensitivity. Modifications to the current workflow increases throughput to 48,000 tests per day while maintaining the identity of each sample. To distinguish between SARS-CoV-2 infection and other respiratory viruses, we will deploy our multiplexed capability to create a pan-respiratory panel. Cost estimates are preliminary based on assumptions of volume and distribution model. To enable pre-symptomatic screening, we are working with the DARPA ECHO program on a host response signature that can be run on the same platform. 2) Scaleup In three months our goal is to scale up manufacturing to over one million tests per day delivering 80 million tests by end of year. Investments in incremental capacity will deliver a cumulative run rate of 4.5 million tests per day in mid 2021. These two components provide a robust platform for scale up of testing for SARS-CoV-2 that allows for the simultaneous detection of other respiratory pathogens.", "keywords": [ "2019-nCoV", "Address", "Biological Assay", "COVID-19 testing", "Clinical", "Detection", "Development", "Goals", "Immune response", "Industry", "Infectious Agent", "Investments", "Microfluidics", "Modeling", "Modification", "Mutation", "RADx", "Reverse Transcriptase Polymerase Chain Reaction", "Running", "SARS-CoV-2 infection", "Sampling", "Sensitivity and Specificity", "Speed", "System", "Testing", "Work", "base", "cost", "cost estimate", "flexibility", "manufacturing scale-up", "programs", "respiratory", "respiratory pathogen", "respiratory virus", "salivary assay", "scale up", "screening", "technology development" ], "approved": true } }, { "type": "Grant", "id": "9115", "attributes": { "award_id": "75N92020C00010-P00001-9999-1", "title": "RADX TECH - TALIS BIOMEDICAL HIGHLY SCALABLE SARS-COV-2 RNA DETECTION IN MINUTES", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Biomedical Imaging and Bioengineering (NIBIB)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2020-07-30", "end_date": "2021-07-29", "award_amount": 9750000, "principal_investigator": { "id": 24901, "first_name": "JENNIFER", "last_name": "BALDWIN", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": null, "abstract": "With over $100M investment by the top biotech Venture Capital funds, NIH, CARB-X, and DARPA, Talis has developed ultrafast, sensitive, scalable technology uniquely suitable for COVID-19 testing. The Talis technology performs rapid (as fast as 6 minutes) purification of SARS-CoV-2 RNA from large volumes of human specimens including swabs and saliva and detects SARS-CoV-2 RNA in under 5 minutes for high positives and under 10 minutes near the limit of detection (~10 copies/reaction). Talis will deploy this technology in a high-throughput format for laboratories (Talis HT) and at the point-of-care (POC) for minimally trained users (Talis One). With RADx support, Talis will scale this technology in three stages: (1) In June, to accelerate throughput of the currently installed diagnostic equipment, Talis will deliver reagent kits for rapid SARS-CoV-2 detection in 96-well format. (2) In July, to further increase testing throughput, Talis will launch automation solutions for common diagnostic laboratory platforms, making kits for 4 million tests available. (3) In September, Talis will launch its rapid COVID-19 Talis One POC test on a multiplexed cartridge, expandable to include influenza. Operated by a compact Talis One instrument, this cartridge enables fully automated, sensitive SARS-CoV-2 RNA detection in under 20 minutes. Talis HT and Talis One will be adaptable to mobile testing for rapid response contact tracing, worker screening, and outbreak response. Talis is requesting RADx support to scale up and accelerate manufacturing of tests and will commit significant funds for cost-sharing.", "keywords": [ "2019-nCoV", "Automation", "Biotechnology", "COVID-19", "COVID-19 detection", "COVID-19 testing", "Capital Financing", "Contact Tracing", "Cost Sharing", "Detection", "Diagnostic", "Diagnostic Equipment", "Disease Outbreaks", "Funding", "Human", "Influenza", "Investments", "Laboratories", "RADx", "RADx Tech", "RNA", "Reaction", "Reagent", "Saliva", "Specimen", "Swab", "Technology", "Testing", "Training", "United States National Institutes of Health", "detection limit", "instrument", "point of care", "point of care testing", "rapid testing", "response", "scale up", "screening" ], "approved": true } } ], "meta": { "pagination": { "page": 1392, "pages": 1419, "count": 14184 } } }